PR Newswire: news distribution, targeting and monitoring
2014

Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators

Share with Twitter Share with LinkedIn

MENLO PARK, Calif., Dec. 3, 2013 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that it has been issued U.S. Patent No. 8,592,640 entitled "Devices and Methods for Dressing Applicators." 

This marks the 7th issued patent in the Neodyne Biosciences portfolio and further supports the company's first product, embrace® Advanced Scar Therapy, which received 510(k) clearance from the US Food and Drug Administration (FDA) in September, 2011. embrace® Advanced Scar Therapy delivers a unique mechanism of action to off-load tension across a newly formed scar, and has been proven to significantly improve scar appearance in a randomized, controlled study.[1]

"Adding another patent to our intellectual property portfolio strengthens our position in the marketplace as we continue to address physician and patient demand for an effective treatment of post-surgical scarring," said Bill Beasley, President of Neodyne Biosciences.

The newly issued patent is owned by Neodyne Biosciences and is accessible on the USPTO's website at www.uspto.gov.

About Neodyne Biosciences, Inc.

Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Investor Relations Contacts:

Bill Beasley

President/COO

bbeasley@neodynebio.com

Randy Haden 

Vice President, Sales

rhaden@neodynebio.com

[1] Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Control Trial. (In press, Plastic and Reconstructive Surgery)

SOURCE Neodyne Biosciences, Inc.



RELATED LINKS
http://www.neodynebio.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 
Area to test

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release